Cost Effectiveness of Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for the First-Line Treatment of Mantle Cell Lymphoma not Eligible for Stem Cell Transplantation- a Scottish Perspective
Abstract
Authors
MM Van Keep K Gairy D Seshagiri P Thilakarathne D Lee